The telehealth company Hims & Hers, known for its weight-loss offerings, now grapples with investor concerns centered on its dependence on compounded GLP-1 agonist drugs. Legal and regulatory uncertainties in this segment threaten long-term viability, especially as original manufacturers defend their market dominance.
New Antitrust Lawsuit Targets GLP-1 Giants
On January 14, 2026, Strive Specialties Inc. filed an antitrust lawsuit against Eli Lilly and Novo Nordisk. The complaint alleges anti-competitive practices aimed at preventing telehealth providers and pharmacies from offering compounded versions of blockbuster GLP-1 drugs like Mounjaro (tirzepatide) and Wegovy (semaglutide).
Although Hims & Hers is not named as a defendant, its growth heavily relies on this market. The case highlights intense competition in the GLP-1 weight loss space and signals aggressive patent protection efforts by pharmaceutical leaders.
Regulatory Risks for Compounded GLP-1s
- If supply shortages of branded drugs like Wegovy and Ozempic resolve, FDA exemptions for pharmacy compounding may end.
- Tighter regulations could limit access to lower-cost compounded alternatives.
- This directly affects telehealth models dependent on compounded semaglutide and tirzepatide for weight management.
Analyst Perspectives on GLP-1 Dependencies
Bank of America maintains an "Underperform" rating, warning that 2026 revenue and margin estimates appear optimistic amid rising investments.
